MIV Therapeutics is developing a next-generation line of ultra thin, polymer-free passive and drug-eluting coatings for cardiovascular stents and a broad range of other implantable medical devices.
The Company's proprietary ultra-thin, hydroxyapatite (HAp) based polymer-free coating has demonstrated excellent safety and biocompatibility in animal studies and human clinical trials for the Companies first hydroxyapatite based product the VESTAsync™ Coronary Drug Eluting Stent System began in May 2007.
In October 2006 the Company’s GenX Coronary Stent System received CE Mark and is currently being marketed in countries honoring the CE Mark through BioSync Scientific, the Company’s wholly owned subsidiary in Surat, India.
MIVT has a Collaborative Research Agreement (CRA) with The University of British Columbia and has received Government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program (NRC-IRAP). In collaboration with the University of British Columbia, the Company has developed unique coating technologies that utilize HAp for application on medical devices and drug delivery systems. MIVT has licensed from the UBC worldwide rights to technologies for coating stents and other medical devices with HAp.
Hydroxyapatite is a naturally occurring porous material that makes up human bone mineral and the matrix of human teeth and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications.
Introduction of new biocompatible polymer-free coatings is expected to provide an attractive alternative to current polymer-based drug-eluting coatings especially in the drug eluting stent market, where it is widely believed that polymers are associated with an increase in undesirable side effects that may be fatal.
